Neuland Laboratories announces financial results for third quarter of fiscal year 2014

Published on February 5, 2014 at 8:13 AM · No Comments

Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2014, ended December 31, 2013.

"In the third quarter of FY2014, Neuland continued to deliver on its commitment to increase profitability," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs. "This partly reflects our focus on growing our higher margin businesses such as our contract manufacturing services, which we believe will serve Neuland well in both the near and longer-term. We also are announcing an upcoming Rights Issue that has been approved by Neuland's Board of Directors. The proceeds are expected to provide resources for investments intended to achieve our strategic business plan and spur additional profitable growth."

Revenues for the third quarter of FY 2014 were $21.15 million (1.308 billion INR*), compared to revenues in the third quarter of FY 2013 of $19.40 million (1.065 billion INR), an increase of 23%.

Neuland reported EBITDA of $3.12 million (193.19 million INR) in the third quarter of FY 2014, compared to EBITDA of $3.22 million (176.56 million INR) in the comparable period in FY 2013, an increase of 9%.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment